Dr Derek Hill, Professor of Digital Health at University College London, on making the most of digital biomarkers and achieving clinical endpoints.

How do we implement the next generation of precision medicines and therapies to optimise patient experience? We sat down with senior representatives from Novartis, Merus, Labcorp, and Simcere Pharmaceuticals to discover the latest industry insights.

Liquid biopsy has the potential to become a transformative cancer management and therapeutic strategy within the next 5 to 10 years. However, its capability across all cancer stages largely depends upon assay sensitivity. In this commentary piece, the University of Edinburgh’s Tim Aitman takes us through a novel approach set to pioneer the landscape of liquid biopsy.

With an increasing need for large data analysis and validation, this Insight article takes an in-depth look at some of the recent advances in automation technologies affecting the flow cytometry field.